ArticleCEN case reports2025
A case of anticoagulation-related nephropathy complicated by IgA nephropathy that developed following the long-term use of anticoagulants.
Article in CEN case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anticoagulant-related nephropathy (ARN) is a critical disease with clinical manifestations including acute kidney injury (AKI), which develops months after drug administration commences. The risk of ARN associated with direct oral anticoagulant agents (DOACs) is lower than that for warfarin, but there have been reports of ARN induced by DOACs other than dabigatran, such as edoxaban. We describe a patient with ARN caused by edoxaban, after the long-term use of warfarin and a switch from dabigatran, who had underlying IgA nephropathy with normal renal function. A 75-year-old man presented with AKI, with hematuria and proteinuria. He had never previously experienced urinary abnormalities or renal impairment. He was started on warfarin for atrial fibrillation 17 years previously, then switched to dabigatran for 11 years, and then edoxaban for 3 years. Three months before admission, he developed melena and hematuria. On the basis of his medical history and renal pathologic findings, he was diagnosed with ARN complicated by IgA nephropathy, with interstitial lesions and marked arteriosclerosis. After discontinuing edoxaban and methylprednisolone pulse therapy followed by oral prednisolone, his proteinuria diminished, and his renal dysfunction and hematuria were ameliorated. ARN can develop at any time in association with any DOAC, even in patients with normal renal function, and may be associated with anticoagulant overdose and subclinical IgA nephropathy. Therefore, careful monitoring of renal function and urinalysis is necessary for the prevention and early recognition of ARN, and dose reduction or a change in anticoagulant should occur when anticoagulant overdose or ARN is suspected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.